Guggenheim Reiterates “Buy” Rating for Centessa Pharmaceuticals (NASDAQ:CNTA)

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports.

Separately, TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $19.03 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The business’s fifty day moving average is $16.77 and its 200 day moving average is $15.44. The company has a market capitalization of $2.51 billion, a PE ratio of -12.44 and a beta of 1.53. Centessa Pharmaceuticals has a fifty-two week low of $7.38 and a fifty-two week high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. Sell-side analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $17.66, for a total transaction of $176,600.00. Following the transaction, the insider now owns 183,266 shares of the company’s stock, valued at approximately $3,236,477.56. This represents a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Saurabh Saha sold 87,496 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the completion of the transaction, the chief executive officer now directly owns 575,661 shares in the company, valued at $10,626,702.06. This represents a 13.19 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 421,697 shares of company stock valued at $7,211,475. 11.59% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in CNTA. Mirae Asset Global Investments Co. Ltd. boosted its position in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC lifted its stake in Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after acquiring an additional 865 shares during the period. Atria Investments Inc raised its stake in shares of Centessa Pharmaceuticals by 7.0% during the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after buying an additional 1,116 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after acquiring an additional 5,316 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in Centessa Pharmaceuticals in the third quarter valued at approximately $187,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.